Clearpoint Neuro Inc reports results for the quarter ended September 30 - Earnings Summary

Clearpoint Neuro

28/10/2026 21:47

Clearpoint Neuro Inc CLPT.OQ reported a quarterly adjusted loss of 24 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -21 cents.  The mean expectation of two analysts for the quarter was for a loss of 31 cents per share. Wall Street expected results to range from -36 cents to -27 cents per share.
Revenue rose 36.3% to $12.08 million from a year ago; analysts expected $12.30 million. 
Clearpoint Neuro Inc's reported EPS for the quarter was a loss of 24 cents​.
The company reported a quarterly loss of $7.46 million.
Clearpoint Neuro Inc shares had fallen by 20.6% this quarter and lost 29.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 19.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is  "buy."
Wall Street's median 12-month price target for Clearpoint Neuro Inc is $23.50, about 58.8% above its last closing price of $9.69
This summary was machine generated from LSEG data October 28 at 09:47 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.31
-0.24
Beat
Jun. 30 2026 
-0.29
-0.38
Missed
Mar. 31 2026 
-0.27
-0.32
Missed
Dec. 31 2025 
-0.20
-0.26
Missed